The IL-6/JAK/STAT3 pathway is aberrantly hyperactivated in many types of cancer, and such hyperactivation is generally associated with a poor clinical prognosis. In the tumour microenvironment, ...IL-6/JAK/STAT3 signalling acts to drive the proliferation, survival, invasiveness, and metastasis of tumour cells, while strongly suppressing the antitumour immune response. Thus, treatments that target the IL-6/JAK/STAT3 pathway in patients with cancer are poised to provide therapeutic benefit by directly inhibiting tumour cell growth and by stimulating antitumour immunity. Agents targeting IL-6, the IL-6 receptor, or JAKs have already received FDA approval for the treatment of inflammatory conditions or myeloproliferative neoplasms and for the management of certain adverse effects of chimeric antigen receptor T cells, and are being further evaluated in patients with haematopoietic malignancies and in those with solid tumours. Novel inhibitors of the IL-6/JAK/STAT3 pathway, including STAT3-selective inhibitors, are currently in development. Herein, we review the role of IL-6/JAK/STAT3 signalling in the tumour microenvironment and the status of preclinical and clinical investigations of agents targeting this pathway. We also discuss the potential of combining IL-6/JAK/STAT3 inhibitors with currently approved therapeutic agents directed against immune-checkpoint inhibitors.
Over 90% of head and neck cancers overexpress the epidermal growth factor receptor (EGFR). In diverse tumor types, EGFR overexpression has been associated with poorer prognosis and outcomes. ...Therapies targeting EGFR include monoclonal antibodies, tyrosine kinase inhibitors, phosphatidylinositol 3-kinase (PI3K) inhibitors, and antisense gene therapy. Few EGFR-targeted therapeutics are approved for clinical use. The monoclonal antibody cetuximab is a Food and Drug Administration (FDA)-approved EGFR-targeted therapy, yet has exhibited modest benefit in clinical trials. The humanized monoclonal antibody nimotuzumab is also approved for head and neck cancers in Cuba, Argentina, Colombia, Peru, India, Ukraine, Ivory Coast, and Gabon in addition to nasopharyngeal cancers in China. Few other EGFR-targeted therapeutics for head and neck cancers have led to as significant responses as seen in lung carcinomas, for instance. Recent genome sequencing of head and neck tumors has helped identify patient subgroups with improved response to EGFR inhibitors, for example, cetuximab in patients with the KRAS-variant and the tyrosine kinase inhibitor erlotinib for tumors harboring MAPK1
E322K
mutations. Genome sequencing has furthermore broadened our understanding of dysregulated pathways, holding the potential to enhance the benefit derived from therapies targeting EGFR.
Women comprise half of the scientific and medical workforce, yet still hold a minority of leadership positions. Here I discuss the barriers to gender equity and offer a new approach to address the ...problem.
Head and neck squamous cell carcinoma Johnson, Daniel E; Burtness, Barbara; Leemans, C René ...
Nature reviews. Disease primers,
11/2020, Letnik:
6, Številka:
1
Journal Article
Recenzirano
Odprti dostop
Most head and neck cancers are derived from the mucosal epithelium in the oral cavity, pharynx and larynx and are known collectively as head and neck squamous cell carcinoma (HNSCC). Oral cavity and ...larynx cancers are generally associated with tobacco consumption, alcohol abuse or both, whereas pharynx cancers are increasingly attributed to infection with human papillomavirus (HPV), primarily HPV-16. Thus, HNSCC can be separated into HPV-negative and HPV-positive HNSCC. Despite evidence of histological progression from cellular atypia through various degrees of dysplasia, ultimately leading to invasive HNSCC, most patients are diagnosed with late-stage HNSCC without a clinically evident antecedent pre-malignant lesion. Traditional staging of HNSCC using the tumour-node-metastasis system has been supplemented by the 2017 AJCC/UICC staging system, which incorporates additional information relevant to HPV-positive disease. Treatment is generally multimodal, consisting of surgery followed by chemoradiotherapy (CRT) for oral cavity cancers and primary CRT for pharynx and larynx cancers. The EGFR monoclonal antibody cetuximab is generally used in combination with radiation in HPV-negative HNSCC where comorbidities prevent the use of cytotoxic chemotherapy. The FDA approved the immune checkpoint inhibitors pembrolizumab and nivolumab for treatment of recurrent or metastatic HNSCC and pembrolizumab as primary treatment for unresectable disease. Elucidation of the molecular genetic landscape of HNSCC over the past decade has revealed new opportunities for therapeutic intervention. Ongoing efforts aim to integrate our understanding of HNSCC biology and immunobiology to identify predictive biomarkers that will enable delivery of the most effective, least-toxic therapies.
Protein tyrosine phosphatase receptor type D (PTPRD) is a putative tumor suppressor in several cancers including head and neck squamous cell carcinoma (HNSCC). STAT3 is a frequently hyperactivated ...oncogene in HNSCC. As STAT3 is a direct substrate of PTPRD, we sought to determine the genetic or epigenetic alterations of PTPRD that contribute to overactive STAT3 in HNSCC.
We analyzed data from The Cancer Genome Atlas (TCGA) and our previous whole-exome sequencing study and summarized the mutation, methylation, and copy number status of PTPRD in HNSCC and other cancers. In vitro studies involved standard transfection and MTT protocols, as well as methylation-specific PCR.
Our findings indicate that PTPRD mutation, rather than methylation or copy number alteration, is the primary mechanism by which PTPRD function is lost in HNSCC. We demonstrate that overexpression of wild-type PTPRD in HNSCC cells significantly inhibits growth and STAT3 activation while PTPRD mutants do not, suggesting that mutation may lead to loss of function and subsequent hyper-phosphorylation of PTPRD substrates, especially STAT3. Importantly, we determined that HNSCC cells harboring an endogenous PTPRD mutation are more sensitive to STAT3 blockade than PTPRD wild-type cells. We additionally found that PTPRD mRNA expression does not correlate with pSTAT3 expression, suggesting that alterations that manifest through altered mRNA expression, including hypermethylation and gene copy number alterations, do not significantly contribute to STAT3 overactivation in HNSCC.
PTPRD mutation, but not methylation or copy number loss, may serve as a predictive biomarker of sensitivity to STAT3 inhibitors in HNSCC.
...the accessibility of the neck structures to fine needle aspirations and direct or computed tomographic-guided core biopsies allows for effective and initial pathologic assessment diagnostic tools ...11-15. ...the terms ameloblastic carcinoma and odontogenic sarcomas were retained, whereas all other descriptive terms including primary, differentiated, and malignant were omitted. Pathology and genetics of head and neck tumours, 3rd ed., 2005, IARC Press, Lyon 3 S. Fleskens, P. Slootweg, Grading systems in head and neck dysplasias: their prognostic value, weakness and utility, Head Neck Oncol, Vol. 1, 2009, 11 4 N Gale, R. Blagus, S.K. Mofty, Evaluation of new grading system for laryngeal squamous intraepithelial lesions-a proposed useful classification, Histopathology, Vol. 65, 2014, 456-464 5 A.J. Kimple, G.K. Austin, R.N. Shah, Polymorphous low grade adenocarcinoma: a case series and determination of recurrence laryngoscope, Vol. 124, 2014, 2714-2719 6 T.D. Patel, A. Vazquez, E. Marchiano, R.C. Park, S. Barendas, J.A. Eloy, Polymorphous low grade carcinoma of the head and neck: a population-based study of 460 cases, Laryngoscope, Vol. 125, 2016, 1644-1649 7 K.K. Ang, J. Harris, R. Wheeler, Human papillomavirus and survival of patients with oropharyngeal cancer, N Engl J Med, Vol. 363, 2010, 24-35 8 A.K. Chaturvedi, E.A. Engels, R.M. Pfeiffer, Human papillomavirus and rising oropharyngeal cancer incidence in the United States, J Clin Oncol, Vol. 29, 2011, 4294-4301 9 M.L. Gillison, Q. Zhang, R. Jordan, Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer, J Clin Oncol, Vol. 30, 2012, 2102-2111 10 M. Lechner, G.M. Frampton, T. Fenton, Genome Med, Vol. 5, 2013, 49 11 A Ferlito, G Bertino, A Rinaldo, G.M. Mannara, K.O. Deneng, A review of heterotopia and associated salivary glands neoplasms of the head and neck, J Laryngol Otol, Vol. 113, 1999, 299-303 13 J Golledge, H Ellis, The etiology of lateral cervical (branchial) cysts: past and present theories, J Laryngol Otol, Vol. 108, 1994, 653-659 14 J.K. La Plante, N.S. Person, G.L. Hedlund, Radiol Clin N Am, Vol. 53, 2015, 181-196 15 C. Garu, L.V. Johansen, J. Jacobsen, P. Gertsen, E. Andersen, B.B. Jensen, Cervical lymph node metastasis from unknown primary tumors. Suppl. 22, 2014, 6057 18 H. Haack, L.A. Johnson, C.J. Fry, Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody, Am J Surg Pathol, Vol. 33, 2009, 984-991 19 S.C. Huang, B.A. Ghossin, J.A. Bishop, Novel PAX3- NCOA1 fusion in biphenotypic sinonasal sarcoma with focal rhabdomyoblastic differentiation, Am J Surg Pathol, Vol. 40, 2016, 51-59 20 J.T. Lewis, A.M. Oliveria, A.G. Nascimento, Low-grade sino-nasal sarcoma with neural and myogenic features: a clinic-pathologic analysis of 28 cases, Am J Surg Pathol, Vol. 36, 2012, 517-525 21 J.S. Reis-Filho, R. Natrajan, R. Valcheva, Histopathology, Vol. 52, 2008, 840-846 22 A Kalova, T Vancek, R Sima, Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity, Am J Surg Pathol, Vol. 34, 2010, 599-608 23 T. Nagao, T.A. Gaffey, D.W. Vischer, Invasive micropapillary salivary duct carcinoma: a distinct histologic variant with biologic significance, Am J Surg Pathol, Vol. 28, 2004, 319-326 24 D Bell, M.E. Kupferman, M.D. Williams, A Rashid, A.K. El-Naggar, Primary colonic-type adenocarcinoma of the base of tongue: a previously unreported phenotype, Hum Pathol, Vol. 40, 2009, 1798-1802 25 A.M. Gillenwater, H. Fatani, A.K. El-Naggar, Primary intestinal-like adenocarcinoma of major salivary glands: 2 instances of previously undocumented phenotype, Head Neck, Vol. 35, 2013, E234-E236 26 R.H. Spiro, A.G. Huvas, E.W. Strong, Adenocarcinoma of salivary origin.
The majority of patients with head and neck squamous cell carcinoma (HNSCC) present with advanced-stage disease. The current standard of care is surgery followed by adjuvant radiotherapy with or ...without chemotherapy or chemoradiation alone. The addition of cetuximab for the treatment of patients with locally advanced or recurrent/metastatic HNSCC has improved overall survival and locoregional control; however, responses are often modest, and treatment resistance is common. A variety of therapeutic strategies are being explored to overcome cetuximab resistance by blocking candidate proteins implicated in resistance mechanisms such as HER2. Several HER2 inhibitors are in clinical development for HNSCC, and HER2-targeted therapy has been approved for several cancers. This review focuses on the biology of HER2, its role in cancer development, and the rationale for clinical investigation of HER2 targeting in HNSCC.
Human papillomavirus (HPV) is a recently identified causative agent for a subset of head and neck cancers, primarily in the oropharynx, and is largely responsible for the rising worldwide incidence ...of oropharyngeal cancer (OPC). Patients with HPV-positive OPC have distinct risk factor profiles and generally have a better prognosis than patients with traditional, HPV-negative, head and neck cancer. Concurrent chemotherapy and radiation is a widely accepted primary treatment modality for many patients with HPV-positive OPC. However, recent advances in surgical modalities, including transoral laser and robotic surgery, have led to the reemergence of primary surgical treatment for HPV-positive patients. Clinical trials are under way to determine optimal treatment strategies for the growing subset of patients with HPV-positive OPC. Similarly, identifying those patients with HPV-positive cancer who are at risk for recurrence and poor survival is critical in order to tailor individual treatment regimens and avoid potential undertreatment.
PDF
